[go: up one dir, main page]

MXPA03003482A - Tratamiento de disfuncion sexual. - Google Patents

Tratamiento de disfuncion sexual.

Info

Publication number
MXPA03003482A
MXPA03003482A MXPA03003482A MXPA03003482A MXPA03003482A MX PA03003482 A MXPA03003482 A MX PA03003482A MX PA03003482 A MXPA03003482 A MX PA03003482A MX PA03003482 A MXPA03003482 A MX PA03003482A MX PA03003482 A MXPA03003482 A MX PA03003482A
Authority
MX
Mexico
Prior art keywords
treatment
sexual dysfunction
antagonists
bombesin receptor
receptor antagonists
Prior art date
Application number
MXPA03003482A
Other languages
English (en)
Inventor
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2000/004380 external-priority patent/WO2002040022A1/en
Priority claimed from GB0109910A external-priority patent/GB0109910D0/en
Priority claimed from GB0111037A external-priority patent/GB0111037D0/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA03003482A publication Critical patent/MXPA03003482A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/344—Disorders of the penis and the scrotum and erectile dysfuncrion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Se ha encontrado que los antagonistas del receptor de bombesina son utiles en el tratamiento de disfuncion sexual tanto en machos como en hembras; pueden ser antagonistas de BB1 selectivos o antagonistas de BB1/BB2 mezclados; se describen combinaciones de los antagonistas del receptor de bombesina con una escala de otros compuestos activos, por ejemplo inhibidores de PDE5, inhibidores de NEP y lasofoxifeno.
MXPA03003482A 2000-11-17 2001-11-14 Tratamiento de disfuncion sexual. MXPA03003482A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2000/004380 WO2002040022A1 (en) 2000-11-17 2000-11-17 Treatment of sexual dysfunction using bombesin antagonist
GB0109910A GB0109910D0 (en) 2001-04-23 2001-04-23 Treatment of sexual dysfunction
GB0111037A GB0111037D0 (en) 2001-05-04 2001-05-04 Treatment of sexual dysfunction
PCT/GB2001/005018 WO2002040008A2 (en) 2000-11-17 2001-11-14 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA03003482A true MXPA03003482A (es) 2004-09-10

Family

ID=27255556

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003482A MXPA03003482A (es) 2000-11-17 2001-11-14 Tratamiento de disfuncion sexual.

Country Status (12)

Country Link
EP (1) EP1333824B1 (es)
JP (1) JP2004522710A (es)
KR (1) KR20030051843A (es)
AT (1) ATE303804T1 (es)
AU (1) AU2002223802A1 (es)
CA (1) CA2429106A1 (es)
DE (1) DE60113290D1 (es)
HU (1) HUP0301892A3 (es)
IL (1) IL155703A0 (es)
MX (1) MXPA03003482A (es)
NZ (1) NZ525415A (es)
WO (1) WO2002040008A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123163A1 (de) 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
US7244743B2 (en) 2002-06-05 2007-07-17 Solvay Pharmaceuticals Gmbh Non-peptidic BRS-3 agonists
EP1575919A1 (en) * 2002-11-11 2005-09-21 Bayer HealthCare AG Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
AU2004312090B2 (en) * 2003-12-31 2008-08-14 The Board Of Regents, The University Of Texas System Pharmaceutical composition for thrombin peptide derivatives
CN102049048B (zh) 2004-12-24 2013-12-25 西芬克斯医药有限公司 治疗或预防的方法
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
AU2007205114B2 (en) * 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
CN102885818B (zh) 2006-03-20 2016-05-04 诺华股份有限公司 治疗或预防炎性痛的方法
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
BR112016029338A2 (pt) 2014-07-29 2017-08-22 Therapeuticsmd Inc creme transdérmico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2018093369A1 (en) * 2016-11-17 2018-05-24 Goren Ofer A Treatment of sexual dysfunction and for improved sexual quality of life

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650395A (en) * 1995-03-13 1997-07-22 Hurel; Steven Treatment of pulmonary hypertension
TR199900364T2 (xx) * 1996-08-22 1999-05-21 Warner-Lambert Company Peptid olmayan bombesin resept�r antagonistleri.
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
ES2258300T3 (es) * 1997-12-16 2006-08-16 Pfizer Products Inc. Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia.
DE19858779A1 (de) * 1998-12-18 2000-06-21 Basf Ag Neue ß-Amido und ß-Sulfonamidocarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
WO2000037462A1 (en) * 1998-12-18 2000-06-29 Warner-Lambert Company Non-peptide nk1 receptors antagonists
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents

Also Published As

Publication number Publication date
EP1333824A2 (en) 2003-08-13
IL155703A0 (en) 2003-11-23
EP1333824B1 (en) 2005-09-07
JP2004522710A (ja) 2004-07-29
NZ525415A (en) 2004-11-26
ATE303804T1 (de) 2005-09-15
HUP0301892A3 (en) 2005-06-28
DE60113290D1 (de) 2005-10-13
HUP0301892A2 (hu) 2003-11-28
CA2429106A1 (en) 2002-05-23
WO2002040008A2 (en) 2002-05-23
WO2002040008A3 (en) 2002-08-22
KR20030051843A (ko) 2003-06-25
AU2002223802A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
MXPA03003482A (es) Tratamiento de disfuncion sexual.
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
WO2001085196A3 (en) Cxcr4 antagonist treatment of hematopoietic cells
WO2001076574A3 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
EP1199069A3 (en) Use of an estrogen agonist/antagonist for assessing, improving, or maintaining urogenital health
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
IL153297A0 (en) Compounds and compositions for delivering active agents
EP1478406A4 (en) COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
ZA200600475B (en) Pyrimidine-2,4-dione derivatives as gonadotripin-releasing hormone receptor antagonists
UA41316C2 (uk) Трициклічні похідні піролу і фармацевтичний препарат
WO2002044183A3 (en) Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
NZ531404A (en) Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
MXPA02009904A (es) Derivados de apomorfina y metodos para su uso.
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
SG149872A1 (en) Antagonists of the bradykinin b1 receptor
WO2002015959A3 (en) Compounds and compositions for delivering active agents
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
BR0115364A (pt) Tratamento de disfunção sexual
EP1199067A3 (en) Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists
AU6846300A (en) Use of cyamemazine for cold turkey benzodiazepine treatment
AU2429399A (en) Combination of an alpha-adrenergic antagonist and a nitrogen oxide donor for treating female sexual dysfunction
MXPA03003481A (es) Tratamiento de disfuncion sexual utilizando antagonista de bombesina.